Comparison of clinical characteristics and outcomes of amiodarone treated patients and control patients
| Amiodarone treated patients (group A) | Control patients (group B) | p Value | |
|---|---|---|---|
| AF, atrial fibrillation; DM, diabetes mellitus; EF, ejection fraction; IHD, ischaemic heart disease; K+, potassium; LAD, left atrial dimension; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; NS, not significant; sinus rhythm, sinus rhythm. | |||
| Data are expressed as mean (SD). | |||
| Number of patients | 17 | 18 | NS |
| Male/female | 14/3 | 15/3 | NS |
| Age (years) | 61.2 (12.3) | 61.6 (7.6) | NS |
| Mean duration of documented AF (months) | 7.2 (4.2) | 10.2 (6.0) | NS |
| Weight (kg) | 85.4 (8) | 85.4 (12.5) | NS |
| Number of patients with ⩾1 previous DEC | 4 | 2 | NS |
| Serum K+ pre-cardioversion (mmol/l) | 4.6 (0.5) | 4.4 (0.5) | NS |
| Number of patients with risk factors for AF | |||
| Hypertension | 11 | 11 | NS |
| IHD | 6 | 3 | NS |
| Lone | 2 | 2 | NS |
| DM | 2 | 1 | NS |
| Number of patients taking rate controlling agents | 16/17 (94.1%) | 17/18 (94.4%) | NS |
| β Blockers | 8/17 | 9/18 | NS |
| Digoxin | 7/17 | 5/18 | NS |
| Rate controlling calcium antagonist | 1/17 | 3/17 | NS |
| EF | 50.2 (13.5%) | 51 (13.0%) | NS |
| LAD (cm) | 4.4 (0.6) | 4.1 (0.8) | NS |
| LVEDD (cm) | 4.8 (0.4) | 4.6 (0.5) | NS |
| LVESD (cm) | 3.4 (0.5) | 3.4 (0.7) | NS |
| Ventricular rate pre-cardioversion (bpm) | 90.8 (14.7) | 88.1 (18.0) | NS |
| Total shock energy used for cardioversion (J) | 454 (331) | 620 (498) | NS |
| Number of shocks utilised | 1.7 (0.9) | 2.2 (1.4) | NS |
| Initial success rate for cardioversion | 17/17 (100%) | 17/18 (94%) | NS |
| SR rate at 6 weeks | 15/17 (88%) | 3/18 (16.7%) | <0.0001 |
| SR rate at 6 months | 11/17 (65%) | 3/18 (16.7%) | 0.0016 |
| At 16 months follow up | 8/17 (47.1%) | 3/18 (16.7%) | 0.075 |